- Conditions
- Unintentional Ingestion of Prescriptions Within Vials and Blisters
- Interventions
- Visual distractor
- Other
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 2 Years to 54 Months
- Enrollment
- 229 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- East Lansing, Michigan • Howell, Michigan • Toledo, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 520
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostatic Cancer, Castration-Resistant
- Interventions
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Portland, Maine • Voorhees Township, New Jersey • The Bronx, New York + 4 more
- Conditions
- Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
- Interventions
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy
- Biological · Drug
- Lead sponsor
- Rapa Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Prostate Cancer
- Interventions
- Talazoparib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 42
- States / cities
- Tempe, Arizona • Duarte, California • Lancaster, California + 23 more
- Conditions
- Multi-Drug Resistant Organism Colonization
- Interventions
- Allogeneic Microbiota in Glycerol (9%) (AMG)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Hinsdale, Illinois + 1 more
- Conditions
- Depression
- Interventions
- Chiropractic Applied Clinical Neuroscience
- Procedure
- Lead sponsor
- Life University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Marietta, Georgia
- Conditions
- Melanoma Stage IV, Solid Tumor
- Interventions
- GIM-531, Anti-PD-1 monoclonal antibody
- Drug
- Lead sponsor
- Georgiamune Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
- Interventions
- XB002, Nivolumab, Bevacizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
- Interventions
- Ponatinib, Chemotherapy Agents
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more
- Conditions
- Obesity & Overweight, Diabetes (DM)
- Interventions
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Increased Drug Resistance, Infectious Diseases
- Interventions
- Intervention: Education, Decision Support Tools
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 3,669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 91
- States / cities
- Mill Valley, California • Oakland, California • San Francisco, California + 31 more
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
- Interventions
- ADC
- Drug
- Lead sponsor
- MBrace Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Imatinib, Sildenafil, Bosentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Weston, Florida • Mineola, New York
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- BNT324, Docetaxel, Prednisone/prednisolone
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 21
- States / cities
- Santa Barbara, California • Aurora, Colorado • Fort Myers, Florida + 17 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Amprenavir, Lamivudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- AZD4635, Oleclumab, Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 6 more
- Conditions
- Refractory Epilepsy
- Interventions
- RWJ-333369
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more
- Conditions
- Breast Cancer
- Interventions
- paclitaxel, antitumor drug screening assay
- Drug · Other
- Lead sponsor
- Oncotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 9
- States / cities
- Fountain Valley, California • Long Beach, California • Los Angeles, California + 5 more
- Conditions
- Alcoholism
- Interventions
- Naltrexone, placebo, Medication Management (MM), Combined Behavioral Intervention (CBI), Telephone Counseling
- Drug · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatitis C, Medication Adherence
- Interventions
- Intensive Models (mDOT and CGT) of HCV Care
- Other
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- Sarah Katie Ihnen
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Epilepsy Intractable
- Interventions
- Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator
- Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 19
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more